فهرست نشریات علمی دسترسی آزاد ایران

Context: Screening programs are a cost-effective way to reduce cervical cancer. Economic evaluation helps health policymakers prioritize high-benefit or more effective healthcare interventions, given the disagreement about the cost-effectiveness of Pap smear, human papillomavirus (HPV) testing, and HPV vaccination in cervical cancer screening. The aim of this study was to compare the cost-effectiveness of Pap smear, HPV test, and HPV vaccination in cervical cancer prevention. Results: The results of the review of studies showed that in most studies, the cost-effectiveness of co-testing is higher than a Pap smear test or the initial HPV test alone. In some studies, the cost-effectiveness was noted to be 2000 euros, and in others, $20,000 per quality-adjusted life year (QALY). There is disagreement about the cost-effectiveness of an annual Pap smear, the HPV test alone, and HPV vaccination in cervical cancer prevention. Conclusions: In most studies, using co-testing has a higher cost-effectiveness than Pap smear alone, so the use of this method is recommended as the most cost-effective approach for the prevention of cervical cancer. However, more studies need to be conducted on the cost-effectiveness of HPV vaccination.